Recommendations for biomarker identification and qualification in clinical proteomics.
about
Distinct cerebrospinal fluid proteomes differentiate post-treatment lyme disease from chronic fatigue syndromeHeat shock proteins as danger signals for cancer detectionMicro-NMR for rapid molecular analysis of human tumor samplesBiomarkers of alcohol misuse: recent advances and future prospectsThe Origin and Activities of IgA1-Containing Immune Complexes in IgA NephropathyPerspectives on systems biology applications in diabetic kidney diseaseBiomarkers of systemic lupus erythematosus identified using mass spectrometry-based proteomics: a systematic reviewUrinary proteomics to support diagnosis of strokeSeminal plasma as a source of prostate cancer peptide biomarker candidates for detection of indolent and advanced diseaseImmunosignature system for diagnosis of cancer.Assessment of metabolomic and proteomic biomarkers in detection and prognosis of progression of renal function in chronic kidney diseaseProof-of-Concept Workflow for Establishing Reference Intervals of Human Urine Proteome for Monitoring Physiological and Pathological Changes.Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuriaAddressing the challenge of defining valid proteomic biomarkers and classifiers.In-depth method assessments of differentially expressed protein detection for shotgun proteomics data with missing values.Proteomic analysis of urinary upper gastrointestinal cancer markers.Is the time ripe for kidney tissue proteomics?Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy.Analysis of the urine proteome via a combination of multi-dimensional approaches.Urinary signatures of Renal Cell Carcinoma investigated by peptidomic approaches.Protein Biomarker Research in UK Hospital Clinical Biochemistry Laboratories: A Survey of Current Practice and ViewsPerformance of different separation methods interfaced in the same MS-reflection TOF detector: a comparison of performance between CE versus HPLC for biomarker analysis.OARSI Clinical Trials Recommendations: Soluble biomarker assessments in clinical trials in osteoarthritis.Why is it so difficult to data mine relevant genome-scale biomarkers?Label-free quantitative urinary proteomics identifies the arginase pathway as a new player in congenital obstructive nephropathy.Added predictive value of omics data: specific issues related to validation illustrated by two case studies.Protein interactome of muscle invasive bladder cancer.Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9.Teaming up for biomarker future. Many problems still hinder the use of biomarkers in clinical practice, but new public-private partnerships could improve the situation.Autoantibody signatures: progress and perspectives for early cancer detectionIntegrated proteomic profiling of cell line conditioned media and pancreatic juice for the identification of pancreatic cancer biomarkers.Magnetic particles in ultrasensitive biomarker protein measurements for cancer detection and monitoring.Quantitative mass spectrometry of urinary biomarkersProtein-Bound Uremic Toxin Profiling as a Tool to Optimize Hemodialysis.Current state of the art for enhancing urine biomarker discovery.Mastitomics, the integrated omics of bovine milk in an experimental model of Streptococcus uberis mastitis: 1. High abundance proteins, acute phase proteins and peptidomics.Quantitative Proteomics Based on Optimized Data-Independent Acquisition in Plasma Analysis.New Insights into the Pathogenesis of IgA Nephropathy.Implementation of proteomic biomarkers: making it work.Defining cancer-related fatigue for biomarker discovery
P2860
Q21135535-C777EE02-F06E-4C7E-B1F9-E23AA87FA014Q24273349-7FE251AE-AD08-4B09-B804-F6EFA3600233Q24603587-88DC345A-8023-4F20-8318-354F105C7023Q26746815-121E77FA-C506-4EF9-A036-074C560DD613Q26752555-6F701084-B279-4349-BE96-5E7637234A28Q26823206-1E810B96-B78E-4CF0-B65B-EB7181D3012FQ28071491-09E876BC-7FC4-4245-9323-A29C38A9DDEDQ28483776-FEC632FC-9413-484C-BD5F-42005E142F67Q28534235-5A519D00-438C-4B35-8060-AFC4C16BFCDAQ30585860-839F2403-40BA-48E3-8468-A676AA780795Q33591146-23D882C1-F362-4788-BD50-7964BE3670B9Q33603691-6FEE7BC1-91D0-4492-B86C-27A5DA2E5F97Q33735287-4FEFADB3-924B-4D37-AEF7-C6C88C7193C4Q33786157-8015BF4A-9B78-4F87-B91C-A04FD7FD7D6EQ33794117-C20ED0C9-84ED-4179-A075-5BE7BCA77557Q33888474-365F06BE-5E85-4C32-A095-E992F2E9F909Q33888480-9DD65ABA-7B6E-489D-8EA6-83505F8A2F13Q33985444-FE43A760-ACB7-471D-80CD-3EE2F81B2874Q34090618-83474BE7-778B-499A-9C99-81EF8ADB58A7Q34155959-85037866-4990-422E-9778-6D7E7D817718Q34158249-8CEBAD66-8520-49CC-962D-7E94A5471FB2Q34208587-833A6A9B-C6D1-495B-982E-80BA7E86AC89Q34475498-0A3E2B69-D8E5-41D6-B251-9783D8D2AFC6Q34619146-3979818F-9B9C-49B5-BA97-88A2DF0777D2Q34634938-55749C29-3428-4FB4-871E-3B0F87FD843BQ34738967-74FE99B7-59F9-4D1A-AD01-D1F2B4D130A7Q34876528-9630CA07-4FCC-464C-B09A-3FCBFB0BD387Q34979033-C256369B-2832-4B2D-96EC-9EEF3B6FBBBAQ35082697-97766B82-98F0-4D57-924D-9C87F43F98BAQ35377236-573ECE16-BB75-47F2-81C8-912DDECCFF46Q35497551-0FF63A5E-09E4-4AE5-A8F4-2BF87AC302B0Q35549676-ABDA241C-71A3-4907-8F12-42EFB518720FQ35599113-20034E9B-5AE4-49DC-B47D-488C791CF78FQ35901218-82DEE157-4F22-44FA-9733-AB04534A82B0Q36032361-0D3084CB-891F-4841-93A8-0163D53A98D7Q36076758-A6ED14F7-38DC-4CED-90F3-FC1165C7D86BQ36229203-B02D609E-1FB2-4800-9EF7-6938B102D111Q36267833-15161228-1142-46AD-8FCE-2A3F8DC42060Q36297774-7BCA9DF9-F98B-428C-BF26-BC757AAD1DEFQ36348914-B9A9710F-05A7-4831-AD86-D6897A326EBC
P2860
Recommendations for biomarker identification and qualification in clinical proteomics.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Recommendations for biomarker identification and qualification in clinical proteomics.
@en
Recommendations for biomarker identification and qualification in clinical proteomics.
@en-gb
Recommendations for biomarker identification and qualification in clinical proteomics.
@nl
type
label
Recommendations for biomarker identification and qualification in clinical proteomics.
@en
Recommendations for biomarker identification and qualification in clinical proteomics.
@en-gb
Recommendations for biomarker identification and qualification in clinical proteomics.
@nl
prefLabel
Recommendations for biomarker identification and qualification in clinical proteomics.
@en
Recommendations for biomarker identification and qualification in clinical proteomics.
@en-gb
Recommendations for biomarker identification and qualification in clinical proteomics.
@nl
P2093
P2860
P50
P1476
Recommendations for biomarker identification and qualification in clinical proteomics.
@en
P2093
Bernard Monsarrat
Bruce A Julian
Dan Theodorescu
Danilo Fliser
Denis Hochstrasser
Eva Weissinger
Franck Molina
Günter Allmaier
Hassan Dihazi
P2860
P304
P356
10.1126/SCITRANSLMED.3001249
P407
P50
P577
2010-08-01T00:00:00Z